Molecular targeted drugs and immune checkpoint blockades are not indicated for all advanced non-small cell lung cancer (NSCLC) cases. For such patients, cytotoxic drugs are the main treatment, and the prognosis remains poor. We present a valuable case of advanced NSCLC that was potentially permanent cured by pemetrexed maintenance chemotherapy.